Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon
- Autori: Petta, S.; Cabibbo, G.; Barbara, M.; Attardo, S.; Bucci, L.; Farinati, F.; Giannini, E.; Tovoli, F.; Ciccarese, F.; Rapaccini, G.; Di Marco, M.; Caturelli, E.; Zoli, M.; Borzio, F.; Sacco, R.; Virdone, R.; Marra, F.; Felder, M.; Morisco, F.; Benvegnã¹, L.; Gasbarrini, A.; Svegliati-Baroni, G.; Foschi, F.; Olivani, A.; Masotto, A.; Nardone, G.; Colecchia, A.; Persico, M.; Boccaccio, V.; Craxi, A.; Bruno, S.; Trevisani, F.; Camma', C.; Biselli, M.; Caraceni, P.; Cucchetti, A.; Domenicali, M.; Piscaglia, F.; Gramenzi, A.; Granito, A.; Magalotti, D.; Serra, C.; Negrini, G.; Napoli, L.; Napoli, L.; Salvatore, V.; Benevento, F.; Gazzola, A.; Murer, F.; Pozzan, C.; Vanin, V.; Moscatelli, A.; Pellegatta, G.; Picciotto, A.; Savarino, V.; Delpoggio, P.; Olmi, S.; Dematthaeis, N.; Balsamo, C.; Vavassori, E.; Roselli, P.; Dell’Isola, S.; Ialungo, A.; Rastrelli, E.; Rini, F.; Costantino, A.; Affronti, A.; Affronti, M.; Mascari, M.; Mega, A.; Pompili, M.; Rinninella, E.; Mismas, V.; Dall’Aglio, A.; Feletti, V.; Lanzi, A.; Cappa, F.; Neri, E.; Stefanini, G.; Tamberi, S.; Biasini, E.; Missale, G.; Guarino, M.; Ortolani, A.; Chiaramonte, M.; Marchetti, F.; Valerio, M.; Aburas, S.; Inghilesi, A.; Cappelli, A.; Golfieri, R.; Mosconi, C.; Renzulli, M.; Coccoli, P.; Zamparelli, M.
- Anno di pubblicazione: 2017
- Tipologia: Articolo in rivista (Articolo in rivista)
- Parole Chiave: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Databases, Factual; Female; Follow-Up Studies; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Retrospective Studies; Catheter Ablation; Pharmacology (medical)
- OA Link: http://hdl.handle.net/10447/248048
Abstract
Background: In HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma (HCC), the time to HCC recurrence and the effects of sustained viral eradication (SVR) by interferon (IFN)-based or IFN-free regimens on HCC recurrence remain unclear. Aim: To perform an indirect comparison of time to recurrence (TTR) in patients with successfully treated early HCC and active HCV infection with those of patients with SVR by IFN-based and by IFN-free regimens. Methods: We evaluated 443 patients with HCV-related cirrhosis and Barcelona Clinic Liver Cancer Stage A/0 HCC who had a complete radiological response after curative resection or ablation. Active HCV infection was present in 328, selected from the Italian Liver Cancer group cohort; 58 patients had SVR achieved by IFN-free regimens after HCC cure, and 57 patients had SVR achieved by IFN-based regimens after HCC cure. Individual data of patients in the last two groups were extracted from available publications. Results: TTR by Kaplan–Meier curve was significantly lower in patients with active HCV infection compared with those with SVR both by IFN-free (P = 0.02) and by IFN-based (P < 0.001) treatments. TTR was similar in patients with SVR by IFN-free or by IFN-based (P = 0.49) strategies. Conclusion: In HCV-infected, successfully treated patients with early HCC, SVR obtained by IFN-based or IFN-free regimens significantly reduce tumour recurrence without differences related to the anti-viral strategy used.